Pharvaris N.V. (PHVS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

SA Transcripts 162.21K Followers Follow Pharvaris N.V. ( PHVS ) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 7:45 AM EDT Company Participants Berndt A. Modig - Co-Founder, CEO & Executive Director Maggie Beller Conference Call Participants Maxwell Skor - Morgan Stanley, Research Division Presentation Maxwell Skor Morgan Stanley, Research Division Great. Thank you very much, everyone, for attending. I'm Max Skor, a biotech analyst with Morgan Stanley. And before we get started, for important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. And with that, I'm very happy to have the Pharvaris team with me today, Berndt Modig, CEO; and Maggie Beller, Head of IR. Thank you very much for joining us. Berndt A. Modig Co-Founder, CEO & Executive Director Thank you, Max. And good to be here. Question-and-Answer Session Maxwell Skor Morgan Stanley, Research Division Great. So maybe we start off. I think this is the third year in a row you've attended. We've sat here at the fireside chat. This is a momentous time in the story of Pharvaris. If you can just maybe step back and give us a brief overview of just how you got here and what are the key steps going forward? Berndt A. Modig Co-Founder, CEO & Executive Director Sure. So actually, our journey or my personal journey in HAE started 23 years ago with -- not with Pharvaris, but with the company that developed icatibant and I worked there together with Jochen Knolle, who is an inventor of icatibant. And then as we all know, Shire took over in 2008, and it then became -- still is the most widely used acute therapy for subcutaneous injection. But already back then, we knew that there was patients were looking for better treatments and already then, we were just starting to think about the vision for an oral therapy.